Cargando…

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects

Detalles Bibliográficos
Autores principales: Dieye, Tandakha N., NDiaye, Birahim P., Dieng, Alle B., Fall, Marema, Brittain, Nathaniel, Vermaak, Samantha, Camara, Makhtar, Diop-Ndiaye, Halimatou, Ngom-Gueye, Ndeye Fatou, Diaw, Papa A., Toure-Kane, Coumba, Sow, Papa S., Mboup, Souleymane, McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805679/
http://dx.doi.org/10.1371/annotation/67550546-cacf-4063-8d62-d165da14ca61
_version_ 1782477898220830720
author Dieye, Tandakha N.
NDiaye, Birahim P.
Dieng, Alle B.
Fall, Marema
Brittain, Nathaniel
Vermaak, Samantha
Camara, Makhtar
Diop-Ndiaye, Halimatou
Ngom-Gueye, Ndeye Fatou
Diaw, Papa A.
Toure-Kane, Coumba
Sow, Papa S.
Mboup, Souleymane
McShane, Helen
author_facet Dieye, Tandakha N.
NDiaye, Birahim P.
Dieng, Alle B.
Fall, Marema
Brittain, Nathaniel
Vermaak, Samantha
Camara, Makhtar
Diop-Ndiaye, Halimatou
Ngom-Gueye, Ndeye Fatou
Diaw, Papa A.
Toure-Kane, Coumba
Sow, Papa S.
Mboup, Souleymane
McShane, Helen
author_sort Dieye, Tandakha N.
collection PubMed
description
format Online
Article
Text
id pubmed-3805679
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38056792013-11-07 Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects Dieye, Tandakha N. NDiaye, Birahim P. Dieng, Alle B. Fall, Marema Brittain, Nathaniel Vermaak, Samantha Camara, Makhtar Diop-Ndiaye, Halimatou Ngom-Gueye, Ndeye Fatou Diaw, Papa A. Toure-Kane, Coumba Sow, Papa S. Mboup, Souleymane McShane, Helen PLoS One Correction Public Library of Science 2013-10-15 /pmc/articles/PMC3805679/ http://dx.doi.org/10.1371/annotation/67550546-cacf-4063-8d62-d165da14ca61 Text en © 2013 Public Library of Science http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Correction
Dieye, Tandakha N.
NDiaye, Birahim P.
Dieng, Alle B.
Fall, Marema
Brittain, Nathaniel
Vermaak, Samantha
Camara, Makhtar
Diop-Ndiaye, Halimatou
Ngom-Gueye, Ndeye Fatou
Diaw, Papa A.
Toure-Kane, Coumba
Sow, Papa S.
Mboup, Souleymane
McShane, Helen
Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
title Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
title_full Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
title_fullStr Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
title_full_unstemmed Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
title_short Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
title_sort correction: two doses of candidate tb vaccine mva85a in antiretroviral therapy (art) naïve subjects gives comparable immunogenicity to one dose in art+ subjects
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805679/
http://dx.doi.org/10.1371/annotation/67550546-cacf-4063-8d62-d165da14ca61
work_keys_str_mv AT dieyetandakhan correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT ndiayebirahimp correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT diengalleb correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT fallmarema correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT brittainnathaniel correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT vermaaksamantha correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT camaramakhtar correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT diopndiayehalimatou correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT ngomgueyendeyefatou correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT diawpapaa correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT tourekanecoumba correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT sowpapas correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT mboupsouleymane correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects
AT mcshanehelen correctiontwodosesofcandidatetbvaccinemva85ainantiretroviraltherapyartnaivesubjectsgivescomparableimmunogenicitytoonedoseinartsubjects